This description refers to T cell receptor (TCR) that bind to tumor Associated antigens (TAA) and allow to specifically recognise cancer cellsTo T lymphocytes expressing the same, Methods for producing the same, and Methods for treating cancer using the same.In particular, this description refers to several variants and their TCR molecules that bind to HLA Class I or II United with a peptide.Which of igf2bp3 - 001 dotado serves la secuencia serves aminoacidos kiqeiltqv (ID n: Eichenberger 1 complaints onThis description refers also to Peptides, Proteins, Nucleic acids and Cells for use in immunotherapeutic methods.In particular, this description refers to Cancer Immunotherapy.This description refers also to Peptide epitopes for t-cells that are associated with Tumors, alone or in combination with other tumor Associated Peptides, e.g.Can serve as active pharmaceutical ingredients in vaccine compositions intended to stimulate antitumor immune responses.To stimulate or ex vivo T lymphocytes which are then transferred to the patients.The peptides bound to Molecules of the major histocompatibility complex (MHC), or peptides as such can also be targets of Antibodies, T Lymphocyte receptor solubleAnd other binding moleculesLa presente descripcion se refiere a receptores de linfocito T (TCR) que se unen a antigenos asociados a tumor (TAA) y que permiten reconocer especificamente celulas cancerosas, a linfocitos T que expresan los mismos, a metodos para producir los mismos, y a metodos para tratar canceres con los mismos. En particular, la presente descripcion se refiere a varios TCR y a sus variantes que se unen a moleculas de HLA de clase I o II unidas con un peptido, como el IGF2BP3-001 dotado de la secuencia de aminoacidos KIQEILTQV (SEQ ID N: 1). La presente descripcion se refiere, ademas, a peptidos, proteinas, acidos nucleicos y celulas destinados a la utilizacion en metodos inmunoterapeuticos. En particular, la presente descripcion se refiere a la inmunoterapia contr
